- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
AIDS Research and Treatment
Volume 2012 (2012), Article ID 478467, 7 pages
Investigation of Super Learner Methodology on HIV-1 Small Sample: Application on Jaguar Trial Data
1INSERM, UMR-S 943, 56 Boulevard Vincent Auriol, BP 335, 75625 Paris Cedex 13, France
2UPMC Univ Paris 06, UMR S943, Paris, France
3Service de Virologie, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France
4Service des Maladies Infectieuses, Hôpital Saint Louis, AP-HP, Paris, France
Received 13 May 2011; Revised 8 November 2011; Accepted 14 January 2012
Academic Editor: Christina Ramirez Kitchen
Copyright © 2012 Allal Houssaïni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- P. Lorenzi, M. Opravil, B. Hirschel et al., “Impact of drug resistance mutations on virologic response to salvage therapy,” AIDS, vol. 13, no. 2, pp. F17–F21, 1999.
- S. Palmer, R. W. Shafer, and T. C. Merigan, “Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development,” AIDS, vol. 13, no. 6, pp. 661–667, 1999.
- J. Aslanzadeh, “HIV resistance testing: an update,” Annals of Clinical and Laboratory Science, vol. 32, no. 4, pp. 406–413, 2002.
- D. Costagliola, D. Descamps, L. Assoumou et al., “Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study,” Journal of Acquired Immune Deficiency Syndromes, vol. 46, no. 1, pp. 12–18, 2007.
- R. W. Shafer, R. Kantor, and M. J. Gonzales, “The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors,” AIDS Reviews, vol. 2, no. 4, pp. 211–228, 2000.
- K. Wang, E. Jenwitheesuk, R. Samudrala, and J. E. Mittler, “Simple linear model provides highly accurate genotypic predictions of HIV-1 drug resistance,” Antiviral Therapy, vol. 9, no. 3, pp. 343–352, 2004.
- R. Kantor, R. Machekano, M. J. Gonzales, K. Dupnik, J. M. Schapiro, and R. W. Shafer, “Human immunodeficiency virus reverse transcriptase and protease sequence database: an expanded data model integrating natural language text and sequence analysis programs,” Nucleic Acids Research, vol. 29, no. 1, pp. 296–299, 2001.
- N. Beerenwinkel, B. Schmidt, H. Walter, et al., “Quantitative phenotype prediction by support vector machines,” Antiviral Therapy, vol. 7, pp. S97–S97, 2002.
- D. Wang, V. DeGruttola, S. Hammer, et al., “A collaborative HIV resistance response database initiative: predicting virological response using neural network models,” Antiviral Therapy, vol. 7, pp. S128–S128, 2002.
- A. D. Sevin, V. DeGruttola, M. Nijhuis et al., “Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS Clinical Trials Group 333,” Journal of Infectious Diseases, vol. 182, no. 1, pp. 59–67, 2000.
- S. Drǎghici and R. B. Potter, “Predicting HIV drug resistance with neural networks,” Bioinformatics, vol. 19, no. 1, pp. 98–107, 2003.
- N. Beerenwinkel, P. Knupfer, and A. Tresch, “Learning monotonic genotype-phenotype maps,” Statistical Applications in Genetics and Molecular Biology, vol. 10, no. 1, article 3, 2011.
- L. Assoumou, F. Brun-Vézinet, A. Cozzi-Lepri et al., “Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response,” Journal of Infectious Diseases, vol. 198, no. 4, pp. 470–480, 2008.
- J. Ravela, B. J. Betts, F. Brun-Vézinet et al., “HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms,” Journal of Acquired Immune Deficiency Syndromes, vol. 33, no. 1, pp. 8–14, 2003.
- A. J. Kandathil, R. Kannangai, O. C. Abraham, S. A. Pulimood, M. A. Jensen, and G. Sridharan, “A comparison of interpretation by three different HIV type 1 genotypic drug resistance algorithms using sequences from non-clade B HIV type 1 strains,” AIDS Research and Human Retroviruses, vol. 25, no. 3, pp. 315–318, 2009.
- L. Assoumou, A. Houssaïni, D. Costagliola, and P. Flandre, “Relative contributions of baseline patient characteristics and the choice of statistical methods to the variability of genotypic resistance scores: the example of didanosine,” Journal of Antimicrobial Chemotherapy, vol. 65, no. 4, pp. 752–760, 2010.
- H. Saigo, A. Altmann, J. Bogojeska, F. Mller, S. Nowozin, and T. Lengauer, “Learning from past treatments and their outcome improves prediction of in vivo response to anti-HIV therapy,” Statistical Applications in Genetics and Molecular Biology, vol. 10, no. 1, article 6, 2011.
- M. J. van der Laan and S. Dudoit, “Unified cross-validation methodology for selection among estimators and a general cross-validated adaptive epsilon-net estimator: finite sample oracle inequalities and examples,” Tech. Rep. number 130, Division of Biostatistics, University of California, Berkeley, Calif, USA, http://www.bepress.com/ucbbiostat/paper130/, 2003.
- M. J. van der Laan and R. Sherri, Targeted Learning: Causal Inference for Observational and Experimental Data, Springer, 2011.
- S. E. Sinisi, E. C. Polley, M. L. Petersen, S. Y. Rhee, and M. J. van der Laan, “Super learning: an application to the prediction of HIV-1 drug resistance,” Statistical Applications in Genetics and Molecular Biology, vol. 6, no. 1, article 7, pp. 1–24, 2007.
- M. J. van der Laan, E. C. Polley, and A. E. Hubbard, Super Learner, Working Paper Series, U.C. Berkeley Division of Biostatistics, 2007.
- E. C. Polley and M. J. van der Laan, Super Learner in Prediction, Working Paper 266, U.C. Berkeley Division of Biostatistics, 2010.
- L. Rosasco, E. de Vito, A. Caponnetto, M. Piana, and A. Verri, “Are loss functions all the same?” Neural Computation, vol. 16, no. 5, pp. 1063–1076, 2004.
- J. M. Molina, A. G. Marcelin, J. Pavie et al., “Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial,” Journal of Infectious Diseases, vol. 191, no. 6, pp. 840–847, 2005.
- I. C. Marschner, R. A. Betensky, V. DeGruttola, S. M. Hammer, and D. R. Kuritzkes, “Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases,” Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 20, no. 3, pp. 220–227, 1999.
- P. Flandre, C. Durier, D. Descamps, O. Launay, and V. Joly, “On the use of magnitude of reduction in HIV-1 RNA in clinical trials: statistical analysis and potential biases,” Journal of Acquired Immune Deficiency Syndromes, vol. 30, no. 1, pp. 59–64, 2002.
- P. Flandre, A. Alcais, D. Descamps, L. Morand-Joubert, and V. Joly, “Estimating and comparing reduction in HIV-1 RNA in clinical trials using methods for interval censored data,” Journal of Acquired Immune Deficiency Syndromes, vol. 35, no. 3, pp. 286–292, 2004.
- S. Y. Rhee, J. Taylor, G. Wadhera, A. Ben-Hur, D. L. Brutlag, and R. W. Shafer, “Genotypic predictors of human immunodeficiency virus type 1 drug resistance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 46, pp. 17355–17360, 2006.
- M. Rabinowitz, L. Myers, M. Banjevic et al., “Accurate prediction of HIV-1 drug response from the reverse transcriptase and protease amino acid sequences using sparse models created by convex optimization,” Bioinformatics, vol. 22, no. 5, pp. 541–549, 2006.
- I. Ruczinski, C. Kooperberg, and M. Leblanc, “Logic regression,” Journal of Computational and Graphical Statistics, vol. 12, no. 3, pp. 475–511, 2003.
- S. E. Sinisi and M. J. van der Laan, “Deletion/substitution/addition algorithm in learning with applications in genomics,” Statistical Applications in Genetics and Molecular Biology, vol. 3, no. 1, article 18, 2004.
- L. Breiman, J. Friedman, C. Stone, and R. A. Olshen, Classification and Regression Trees, Chapman and Hall/CRC, 1984.
- L. Breiman, “Random forests,” Machine Learning, vol. 45, no. 1, pp. 5–32, 2001.
- M. C. F. Prosperi, A. Altmann, M. Rosen-Zvi et al., “Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment,” Antiviral Therapy, vol. 14, no. 3, pp. 433–442, 2009.
- A. G Marcelin, P. Flandre, J. Pavie, et al., “New genotypic score comprising mutations impacting negatively and positively the virological response to didanosine in treatment-experienced patients from the randomized didanosine add on Jaguar study,” Antiviral Therapy, vol. 9, pp. U102–U102, 2004.
- B. Masquelier, K. L. Assoumou, D. Descamps et al., “Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir,” Journal of Antimicrobial Chemotherapy, vol. 61, no. 6, pp. 1362–1368, 2008.
- S. Vora, A. G. Marcelin, H. F. Günthard et al., “Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients,” AIDS, vol. 20, no. 1, pp. 35–40, 2006.
- P. Flandre, A. G. Marcelin, J. Pavie et al., “Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar study,” Antiviral Therapy, vol. 10, no. 4, pp. 479–487, 2005.
- A. G. DiRienzo, V. DeGruttola, B. Larder, and K. Hertogs, “Non-parametric methods to predict HIV drug susceptibility phenotype from genotype,” Statistics in Medicine, vol. 22, no. 17, pp. 2785–2798, 2003.